Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pharmacokinetics of Ferric bepectate - a new intravenous iron drug for treating iron deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996-2013

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. [Sar1, Ile4, Ile8]-angiotensin II Potentiates Insulin Receptor Signalling and Glycogen Synthesis in Hepatocytes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Long-term effects of cardiac rehabilitation after heart valve surgery - results from the randomised CopenHeartVR trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Three decades of heart transplantation: experience and long-term outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Refractory in-hospital cardiac arrest - no time to waste

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  4. Self-assessed health status and associated mortality in endocarditis: secondary findings from the POET trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: The sodium-glucose co-transporter-2 (SGLT2) inhibitors were developed as glucose-lowering drugs to treat type 2 diabetes (T2D). However, significant reductions in clinical outcomes have now been demonstrated in patients with heart failure with reduced ejection fraction (HFrEF), irrespective of the presence of T2D. Multiple hypotheses have been proposed for the underlying mechanisms, and the data to support these proposals are emerging.

OBJECTIVES: To review the clinical outcome data with SGLT2 inhibitors in HFrEF and the data to support the mechanisms for these clinical effects.

METHODS: Literature review was supported by a PubMed search for relevant articles up to 19 April 2022.

FINDINGS: Current data support increased diuresis and reverse cardiac remodelling as important mechanisms for the reductions in heart failure hospitalizations and mortality observed with SGLT2 inhibitors (empagliflozin or dapagliflozin) in patients with HFrEF. Alteration in intrarenal haemodynamic is likely contributing to the observed renoprotective effect of SGLT2 inhibitors.

CONCLUSIONS: Solid clinical data support the current recommendations to use empagliflozin or dapagliflozin in HFrEF. The underlying mechanisms likely include changes in cardiac and intrarenal haemodynamic. Yet, these mechanisms do not seem to solely explain the observed magnitude of clinical effect with SGLT2 inhibitors in HFrEF, and other mechanisms may contribute.

OriginalsprogEngelsk
TidsskriftBasic & clinical pharmacology & toxicology
Vol/bind131
Udgave nummer1
Sider (fra-til)5-17
Antal sider13
ISSN1742-7843
DOI
StatusUdgivet - jul. 2022

Bibliografisk note

This article is protected by copyright. All rights reserved.

ID: 77928623